NASDAQ
16.01.26 | 22:00
4,370 US-Dollar
-0,46 % -0,020
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| POLYPID Aktie jetzt für 0€ handeln | |||||
| 31.12.25 | PolyPid Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 16.12.25 | PolyPid Appoints Brooke Story As Chairman Of Board | 3 | RTTNews | ||
| 16.12.25 | PolyPid Ltd.: PolyPid Appoints Veteran MedTech Leader Brooke Story as Chairman of the Board of Directors | 1 | GlobeNewswire (USA) | ||
| 16.12.25 | PolyPid Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 09.12.25 | PolyPid: Interview With Chief Operating Officer - U.S. Operations Ori Warshavsky About Preventing Surgical Site Infections | 1 | pulse2.com | ||
| 03.12.25 | FDA unterstützt Zulassungsantrag für D-PLEX100: PolyPid-Aktie legt zu | 3 | Investing.com Deutsch | ||
| 03.12.25 | PolyPid Ltd.: PolyPid Announces Positive FDA Pre-NDA Meeting Minutes for D-PLEX100 Supporting NDA Submission | 104 | GlobeNewswire (Europe) | PETACH TIKVA, Israel, Dec. 03, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced... ► Artikel lesen | |
| 01.12.25 | PolyPid stock rating reiterated at Market Outperform by Citizens | 3 | Investing.com | ||
| 26.11.25 | PolyPid Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 25.11.25 | PolyPid Ltd.: PolyPid to Participate in ROTH Capital Partners Virtual KOL Event on December 10, 2025 | 2 | GlobeNewswire (USA) | ||
| 12.11.25 | PolyPid Ltd. Q3 Loss Decreases, Beats Estimates | 1 | RTTNews | ||
| 12.11.25 | PolyPid GAAP EPS of -$0.37 beats by $0.15 | 2 | Seeking Alpha | ||
| 12.11.25 | PolyPid Ltd.: PolyPid Provides Corporate Update and Reports Third Quarter 2025 Financial Results | 126 | GlobeNewswire (Europe) | Face-to-Face Pre-NDA Meeting with the FDA Scheduled for Early December; NDA Submission for D-PLEX100 On Track for Early 2026 Advancements in Discussions with Potential U.S. Partners Following Positive... ► Artikel lesen | |
| 12.11.25 | PolyPid Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 06.11.25 | PolyPid Ltd.: PolyPid's D-PLEX100 Wins BioTech Breakthrough Award for "Therapeutics Solution of the Year" | 1 | GlobeNewswire (USA) | ||
| 29.10.25 | PolyPid Ltd.: PolyPid to Report Third Quarter 2025 Financial Results and Operational Highlights on November 12, 2025 | 1 | GlobeNewswire (USA) | ||
| 30.09.25 | PolyPid: Starke Phase-3-Daten für D-PLEX100 - US-Partner für Markteinführung gesucht | 2 | Investing.com Deutsch | ||
| 30.09.25 | PolyPid Ltd.: PolyPid to Present Its Positive Phase 3 SHIELD II Topline Results at the 2025 American College of Surgeons Clinical Congress | 1 | GlobeNewswire (USA) | ||
| 16.09.25 | PolyPid Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 16.09.25 | PolyPid Ltd.: PolyPid Successfully Completes Israeli Ministry of Health GMP Inspection, Advancing Towards Commercial Manufacturing Readiness for D-PLEX100 | 1 | GlobeNewswire (USA) |
1 2 Weiter >>
30 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 94,00 | +0,05 % | BioNTech: FDA vergibt Orphan-Drug-Status für Gotistobart | Die BioNTech SE und OncoC4, Inc. haben von der U.S. Food and Drug Administration (FDA) den Orphan-Drug-Status für Gotistobart (BNT316/ONC-392) zur Behandlung des Plattenepithelkarzinoms der Lunge erhalten.... ► Artikel lesen | |
| EVOTEC | 6,308 | -0,28 % | Aktien KW 2 - Rekordlauf. Fortsetzung folgt? News. Mutares. SFC Energy. Evotec. Nordex. Grenke. Teamviewer. Rheinmetall. Circus. Planethic Group | Aktien: DAX über25.000 Punkte, neue Rekorde. Und das trotz völkerrechtswidrigem Venezuela-Coup, weiterer Unsicherheit in der Ukraine, Streit zwischen Saudis und Emiratis. Politik tritt zurück, fundamental... ► Artikel lesen | |
| AMGEN | 285,90 | +0,35 % | Amgen Reports MariTide Weight Loss Holds Up With Fewer Doses | ||
| VIKING THERAPEUTICS | 29,425 | +0,60 % | Viking Therapeutics, Inc.: Viking Therapeutics Announces Publication of Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in the Journal Obesity | Publication Highlights Impressive Weight Loss of Up to 14.7% from Baseline After 13 Weeks of Treatment; No Plateau Observed
VK2735 Currently Being Evaluated in... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,410 | +1,49 % | Defence Therapeutics Inc.: Defence Therapeutics Announces AGM Results and Provides Corporate Updates | Montreal, Quebec--(Newsfile Corp. - December 10, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a biotechnology company advancing a proprietary... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,397 | -2,93 % | NurExone Biologic Inc. nimmt an der J.P. Morgan Healthcare Week 2026 teil | ||
| ABIVAX | 101,20 | -0,59 % | Abivax schießt nach oben: Macht Eli Lilly jetzt ernst? | Seit Wochen kursieren Übernahmespekulationen rund um das franzöische Biotech-Unternehmen Abivax. Der US-Pharmariese El Lilly soll interessiert sein. Nun kochen die Gerüchte erneut hoch: rund 15 Milliarden... ► Artikel lesen | |
| IBIO | 1,900 | -0,52 % | iBio, Inc. - 8-K, Current Report | ||
| ARROWHEAD PHARMACEUTICALS | 55,40 | +0,62 % | Arrowhead Pharma stock maintains Overweight rating at Cantor Fitzgerald | ||
| VOYAGER THERAPEUTICS | 3,326 | +2,46 % | Voyager Therapeutics, Inc.: Transition Bio and Voyager Announce Collaboration to Advance Small Molecules Targeting TDP-43 in ALS and Frontotemporal Dementia | CAMBRIDGE, United Kingdom and LEXINGTON, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Transition Bio, a drug discovery company focused on unlocking traditionally "undruggable" targets by leveraging biomolecular... ► Artikel lesen | |
| CYBIN | 6,700 | +0,75 % | Neural Therapeutics: Mit Meskalin gegen die globale Krise der psychischen Gesundheit | ||
| CAPRICOR | 20,500 | -2,38 % | Capricor Therapeutics stock rating reiterated by Cantor Fitzgerald | ||
| OPGEN | 2,600 | 0,00 % | OPGEN INC - 8-K, Current Report | ||
| MEREO BIOPHARMA | 0,574 | +4,36 % | MEREO BIOPHARMA zeigt klare innere Stärke | ||
| APELLIS PHARMACEUTICALS | 17,250 | +0,40 % | Apellis stock rating reiterated at Overweight by Cantor Fitzgerald |
Das Unternehmen POLYPID LTD kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 4,370 Euro und damit -0,46 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu POLYPID LTD finden Sie auf Wallstreet Online.